Startup Funding

Menu
Subscribe
Search
The Art and Science of Screening a Deal

The Art and Science of Screening a Deal

•
Fundraising, Investing

Related Guides

    Search Startupfunding above or view our

    The Art and Science of Screening a Deal

    7 min read The Art and Science of Screening a Deal: How investors can use first-pass filters, scoring matrices, and data-driven checklists to identify high-potential startups faster.   Early-stage investing isn’t about finding certainty—it’s about filtering signal from noise efficiently. With inbound deal flow at all-time highs, the real bottleneck for angels, family offices, and funds is no longer access to opportunities, but decision velocity with discipline. The best investors don’t evaluate every deck equally; they apply structured screening systems that surface the few opportunities worth deeper diligence. Screening is both an art and a science. The science lives in repeatable filters, scoring models, and objective criteria. The art lies in judgment—knowing when a company breaks the rules for the right reasons. Below is a practical, investor-ready framework for building a strong first-pass screening process that saves time, reduces bias, and improves outcomes. 1. First-Pass Filters: Decide What Doesn’t Belong Before scoring, eliminate misalignment early. First-pass filters should answer one question quickly: Is this deal even worth time? a. Stage & Check Size Fit Most deals fail here. Clarify upfront: Revenue or traction stage (pre-seed, seed, growth Typical check size and ownership targets Ability to follow on If the company doesn’t fit your mandate, pass fast and clean. b. Sector & Thesis Alignment Avoid “interesting but off-strategy” traps. Screen for: Core sectors, you understand Problems you believe matter Markets where you have pattern recognition Thesis discipline compounds over time. c. Geography & Jurisdiction Regulatory and operational friction varies widely. Filter based on: Geographic focus Regulatory exposure ,you’re comfortable underwriting Ability to support the company post-investment First-pass filters protect focus and bandwidth. 2. Scoring Matrices: Bring Structure to Subjectivity Once a deal clears initial filters, apply a simple scoring matrix to compare opportunities consistently. a. Core Dimensions to Score Limit scores to what actually predicts outcomes: Founder–market fit Traction quality Market clarity Capital efficiency Execution readiness Avoid over-scoring vision or TAM in isolation. b. Use Relative, Not Absolute Scores Scores matter most across your own deal set, not in isolation. Ask: Is this stronger or weaker than other deals this month? Where does it rank in the top 10–20%? This sharpens prioritization. c. Weight What You Value Not all factors are equal. For example: Early-stage angels may weigh founders higher Family offices may weigh downside protection and governance Funds may weigh scalability and exit paths Scoring systems should reflect your capital’s objectives. 3. Data-Driven Checklists: Reduce Bias, Increase Speed Checklists ensure you ask the same questions every time—especially under time pressure. a. Founder & Team Checklist Look for: Clear role ownership Evidence of execution together Coachability and learning velocity Gaps the team acknowledges (not denies) Red flag: defensiveness over curiosity. b. Traction & Market Checklist Validate: Who is paying (or piloting) and why Repeatability across similar customers Clear ICP definition Sales cycle realism Green flag: founders can explain why deals don’t close. c. Financial & Capital Checklist Screen for: Burn vs. milestones achieved Clean cap table Use-of-funds clarity Runway awareness Early financial hygiene predicts later governance quality. 4. Pattern Recognition: Compare to Known Outcomes Great screeners constantly ask: What does this remind me of? a. Positive Patterns Look for signals you’ve seen before: Second-time founders correcting past mistakes Early customers behaving like reference buyers Clear narrowing of focus over time b. Risk Patterns Watch for recurring failure modes: “Too many use cases.” Revenue driven by one non-repeatable customer Fundraising as the strategy Pattern recognition improves with documentation—write down why you passed. 5. Decision Buckets: Triage, Don’t Debate Every screened deal should land in one of three buckets: Advance → deeper diligence Monitor → stay close, request updates Pass → clear, respectful decline The goal is not perfection; it’s momentum with clarity. Strong investors don’t win by seeing more deals; they win by screening better. First-pass filters protect focus. Scoring matrices create consistency. Checklists reduce bias. Together, they allow investors to move faster without sacrificing rigor. Screening is not about saying “no” more often; it’s about saying “yes” with conviction when it matters. The best deals don’t always look perfect at first glance, but the best investors know exactly why they’re leaning in. Want to professionalize your deal screening process? Join our investor community to access proven screening templates, scoring matrices, and diligence frameworks designed to help you identify high-potential startups faster—before the rest of the market catches on.

    Read More »

    Critical Success Factors in Early-Stage Diligence

    5 min read Critical Success Factors in Early-Stage Diligence: The Five Attributes That Consistently Predict Startup Success Early-stage investing is not about eliminating risk; it’s about understanding which risks matter and which signals actually correlate with outcomes. While pitch decks highlight vision, market size, and upside, long-term success is far more consistently driven by a small set of fundamentals that recur across winning companies. Whether you’re an angel investor, family office, strategic, or venture fund, diligence on early-stage companies requires a disciplined lens focused on execution, capital behavior, and clarity—not hype. Below is a structured, investor-ready framework outlining the five critical success factors that most reliably predict early-stage startup success. 1. Founder–Market Fit   a. Domain Insight & Lived Experience Founder–market fit goes beyond credentials. It reflects whether founders deeply understand the customer problem because they’ve lived it. Evaluate: Prior industry experience or operator background Direct exposure to the customer pain point Nuanced understanding of buyer behavior and constraints Strong founder–market fit often shows up in how founders talk about edge cases, objections, and tradeoffs, not just the headline problem. b. Credibility with Customers & Stakeholders Ask whether the founder can earn trust quickly. Look for: Early customer champions Warm intros to buyers or partners Advisory relationships rooted in the market Founders with real market credibility shorten sales cycles and reduce go-to-market risk. c. Learning Velocity Markets change. Strong founders adapt. Assess: How assumptions have evolved over time Willingness to admit what didn’t work Speed of iteration based on customer feedback Founder–market fit is dynamic; it strengthens through learning, not stubbornness. 2. Repeatable Traction (Not Vanity Metrics)   a. Evidence of Pull, Not Push Early traction should demonstrate customer pull, not founder-driven hustle alone. Validate: Repeat customers or expansions Conversion consistency across similar customer profiles Willingness to pay—not just pilot participation Traction that repeats is far more predictive than one-off wins. b. Sales Motion Clarity Understand how the company wins customers. Ask: Is the sales process repeatable or bespoke? Are cycle times shortening or lengthening? Is founder involvement decreasing over time? Repeatable traction signals that growth can scale beyond the founding team. c. Cohort Behavior Dig into cohort data where possible. Look for: Retention trends Usage depth over time Expansion or upsell behavior Strong cohorts often matter more than top-line growth at early stages. 3. Capital Efficiency & Discipline   a. Burn vs. Learning Capital efficiency is not about spending less; it’s about spending with intent. Evaluate: Burn relative to milestones achieved Whether spending is tied to risk reduction Headcount growth aligned with revenue or learning Efficient teams buy time and optionality. b. Milestone-Based Planning Strong teams know exactly what the next dollar unlocks. Ask: What milestones justify the next raise? What risks are reduced with the current capital? What happens if fundraising takes longer than expected? Capital discipline often separates survivors from casualties. c. Downside Awareness Founders who understand downside are more investable. Look for: Runway scenarios Clear cost controls Willingness to slow growth to preserve optionality Optimism without contingency is a red flag. 4. Defensible IP or Structural Moats   a. Nature of Defensibility Defensibility doesn’t have to mean patents—but it must exist. Assess: Intellectual property (patents, trade secrets) Data advantages Switching costs Workflow or ecosystem lock-in Ask whether differentiation widens or narrows as the company grows. b. Replication Risk Pressure-test how easy it would be to copy the product. Consider: Time to replicate core functionality Capital required to compete Customer switching friction If incumbents can replicate quickly, speed and distribution must compensate. c. Strategic Relevance Defensibility increases when the company sits at a strategic choke point. Look for: Integration into core workflows Control over critical data or insights Alignment with long-term industry shifts Moats compound over time—but only if designed intentionally. 5. Cash-Flow Clarity & Financial Transparency   a. Revenue Quality Understand where revenue really comes from. Evaluate: Recurring vs. one-time revenue Contract length and renewal behavior Revenue concentration risk Predictable revenue reduces financing risk. b. Unit Economics Visibility Even pre-revenue companies should understand their economics. Ask: What does profitability look like at scale? Where do margins expand or compress? What assumptions matter most? Clarity matters more than perfection. c. Financial Hygiene Transparency builds trust. Look for: Clean cap tables Clear use-of-funds plans Consistent financial reporting Messy finances early often signal deeper execution issues later. Final Thoughts Early-stage success is rarely random. While outcomes are never guaranteed, the same attributes recur in companies that scale, survive, and return capital. By focusing diligence on founder–market fit, repeatable traction, capital efficiency, defensible moats, and cash-flow clarity, investors dramatically improve their odds of backing teams that can navigate uncertainty and compound value over time. Great investors don’t chase stories—they evaluate fundamentals with discipline.  

    Read More »

    How to Diligence a Deal Beyond the Deck

    10 min read How to Diligence a Deal Beyond the Deck A practical framework for investors to go deeper than the pitch—focusing on risk domains, capital discipline, and founder transparency. Pitch decks are designed to persuade, not to fully inform. They highlight upside, compress complexity, and often gloss over risk. For investors, relying on the deck alone is one of the fastest ways to misprice risk and overestimate execution. Whether you’re an angel investor, family office, strategic, or venture fund, diligence on a deal beyond the deck requires a structured, skeptical, and evidence-driven approach. The goal isn’t to kill deals to build conviction by understanding where things can break and whether the team has the discipline to navigate those risks. Below is a practical framework to go deeper than the pitch and evaluate a company across its true risk domains. 1. Business Model Clarity & Unit Economics   a. How the Company Actually Makes Money Start by stress-testing the revenue model—not the TAM slide. Ask: Is revenue transactional, recurring, usage-based, or contract-driven? Who is the buyer vs. the end user? What triggers revenue recognition? Break down cost drivers: COGS or service delivery costs Sales commissions and customer success Infrastructure, tooling, or third-party dependencies Look for: Clear margin expansion logic Evidence that costs decline with scale, not just assumptions If unit economics don’t work at a small scale, they rarely work later. b. LTV, CAC, and Payback Reality Founders often present optimistic LTV/CAC ratios. Your job is to pressure-test them. Validate: CAC by channel (not blended averages) Sales cycle length by customer segment Retention, expansion, and churn assumptions Ask: How long does it take to recover CAC on a cash basis? What happens to CAC as the company scales? Are early customers representative—or exceptions? c. Pricing Power & Market Sensitivity Understand whether pricing is: Cost-plus Value-based Competitive or commoditized Test: What happens if prices drop 20%? Can customers easily switch? Is pricing driven by ROI, urgency, or convenience? Real businesses survive pricing pressure. Fragile ones don’t. 2. Risk Domains: Where the Business Can Break Great diligence maps risk before upside. Key risk domains to assess: Market risk (is the problem real and urgent?) Product risk (does it work as claimed?) Execution risk (can the team deliver?) Financial risk (capital sufficiency and burn discipline) Regulatory or compliance risk (if applicable) Dependency risk (customers, vendors, platforms) Ask founders directly: “What are the top three things that could kill this company?” How they answer matters as much as what they say. 3. Product Reality vs. Product Narrative   a. Product-Market Fit Evidence Look for proof—not promises. Validate through: Customer usage data Retention and engagement metrics Pilot-to-paid conversion rates Reference calls with real users Red flags: Heavy roadmap focus with light customer evidence Features driving excitement but not retention “Design partners” that never convert b. Roadmap Discipline A strong roadmap is prioritized, resourced, and sequenced. Ask: What gets built next—and why? What’s customer-driven vs. founder-driven? What milestones unlock revenue or margin? Avoid teams chasing breadth before depth. 4. Go-to-Market Execution   a. Sales Motion Fit Evaluate whether the GTM motion aligns with the product and the buyer. Assess: Self-serve vs. sales-led vs. enterprise Founder-led sales dependency Channel vs. direct strategy Red flags: Long enterprise cycles without a capital runway Complex sales motions with junior teams No clear ICP definition b. Pipeline Quality Inspect pipeline health—not just top-line numbers. Look for: Stage conversion rates Deal slippage patterns Customer concentration risk One “logo” does not equal traction. 5. Founder Transparency & Integrity This is where diligence moves from analytical to judgment-based. Strong founders: Share bad news early Acknowledge weaknesses Provide clean, consistent data Don’t over-defend assumptions Watch for: Shifting answers across meetings Overly polished responses to hard questions Resistance to data requests Trust is built through consistency under pressure. 6. Team & Execution Capacity   a. Role Coverage Evaluate whether critical functions are owned: Product Sales Operations Finance Early-stage teams don’t need depth everywhere—but they need awareness of gaps. b. Execution Track Record Ask: What milestones were hit late—and why? Where has the team over- or under-estimated? How do they course-correct? Past execution is the best predictor of future execution. 7. Financial Discipline & Capital Strategy   a. Burn vs. Learning Healthy burn drives learning and de-risking—not just growth optics. Assess: Monthly burn vs. milestone progress Headcount growth vs. productivity Spend aligned to key risks   b. Capital Plan Reality Understand: How long does the current capital last What milestones justify the next raise Downside survival scenarios Ask: “If fundraising takes 6 months longer than expected, what happens?” 8. Cap Table & Incentive Alignment Review: Ownership distribution SAFEs, notes, and preference stacks Employee option pool health Red flags: Overcrowded early cap tables Misaligned investor rights Founder dilution that kills motivation 9. Market Context & Competitive Positioning Map: Direct competitors Indirect substitutes Incumbent responses Assess: Switching costs Differentiation durability Speed of competitive response Winning often depends on timing, not just product quality. 10. Exit Logic & Investor Fit   a. Plausible Exit Paths Ask: Who buys companies like this? At what scale? On what metrics? Hope is not a strategy, exits follow patterns. b. Alignment Check Finally, assess: Time horizon fit Risk tolerance alignment Strategic vs. financial expectations A good deal for someone else can be a bad deal for you. Final Thoughts Diligencing a deal beyond the deck is about discipline, curiosity, and humility. It means resisting the story long enough to examine the structure underneath—and deciding whether the risks are known, manageable, and worth taking. By applying a structured framework, grounded in unit economics, risk domains, founder transparency, and capital discipline, you move from guessing to conviction. The best investors don’t avoid risk. They understand it better than anyone else in the room.   Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

    Read More »

    How to Diligence a Cleantech Firm

    7 min read How to Diligence a Cleantech Firm Diligence for a cleantech firm requires a different lens than for traditional software, CPG, or marketplace investing. Whether you’re an angel investor, family office, strategic, or VC, evaluating a cleantech business means examining technology readiness, regulatory compliance, unit economics, carbon impact, capital intensity, and infrastructure dependencies. Here’s a structured, risk-aware playbook to diligence a cleantech company with confidence. 1. Understand the Business Model & Unit Economics   a. Revenue Model & Cost Structure Determine whether the company generates revenue through hardware sales, SaaS layers, project development, installation contracts, or long-term service agreements (e.g., O&M or energy-as-a-service). Break down COGS: components, engineering labor, installation, freight, commissioning, and warranty obligations. Ask how margins improve with volume: Are hardware components commoditized or proprietary? Do economies of scale significantly reduce manufacturing costs? Are service contracts profitable over their lifecycle? b. Lifetime Value (LTV) & Customer Acquisition Costs (CAC) For enterprise or municipal customers: What is the expected contract term? How often do customers expand deployments? What is the churn for service agreements? For residential solutions (e.g., solar installers, battery providers): Evaluate gross profit per project. Compare customer lifetime profit to CAC and installation labor costs. c. Pricing Strategy How price-sensitive is the market? Does the company compete on cost savings, performance, or sustainability ROI? How do market incentives (tax credits, grants, utility rebates) affect pricing? Ensure the pricing model remains viable even if subsidies decrease or competition intensifies. 2. Technology Readiness & Scalability Risks   a. Technology Validation (TRL Levels) Assess technology readiness: Has it been lab-validated, pilot-tested, or commercially deployed? Request: Independent validation reports Performance data Warranty or reliability metrics Identify any unproven assumptions that could hinder commercialization. b. Manufacturing & Supply Chain Where and how is the product manufactured? In-house, outsourced, or contract manufacturing? Are critical components single-source (e.g., rare earth metals, lithium cells)? Evaluate supply-chain resiliency: Lead times Supplier diversification Exposure to geopolitical risk c. Scalability Constraints Does scaling require: Large capex investment? Specialized labor? Utility interconnection approval? Local permitting or environmental assessments? Assess whether physical constraints—not just demand—could limit growth. 3. Market & Go-to-Market Strategy   a. Target Market & Adoption Curve Who are the customers—utilities, industrials, municipalities, real estate developers, corporates, or consumers? Analyze: Market size Market fragmentation Regulatory tailwinds (e.g., IRA incentives, net metering policy) Determine if the market is ready for the solution or if customer education will slow sales cycles. b. Sales Model & Distribution Is the company using direct sales, channel partners, installers, EPCs, or distributors? For enterprise or government sales: Review sales cycle length Contract structure RFP dependency Proof of traction with anchor customers c. Customer Proof & Brand Positioning Evaluate customer testimonials, commercial pilots, and measurable outcomes (e.g., kWh reduction, CO₂ saved, O&M savings). Assess whether the company’s differentiation—performance, sustainability, cost savings, or reliability—is real and defensible. 4. Regulatory, Policy & Compliance Considerations   a. Certifications & Safety Request certification documents such as: UL, CE, ISO standards Grid interconnection compliance (e.g., IEEE standards) Environmental or emissions certifications Check whether the product has undergone third-party testing. b. Policy Dependencies Many cleantech firms depend on incentives. Understand: How the business performs with and without subsidies Risks from policy changes Exposure to tariffs, import duties, or trade restrictions c. Permitting, Interconnection & Local Regulations For grid-dependent products: Interconnection timelines Utility approval processes Permitting risks For environmental tech: EPA, state-level environmental regulation Potential liabilities (e.g., waste handling, emissions compliance) 5. Product & Innovation Pipeline   a. Product-Market Fit Review pilot results, customer feedback, reliability metrics, uptime rates, and warranty claims. Evaluate whether early adopters are becoming long-term customers, and whether the product delivers measurable ROI. b. R&D Roadmap Ask for: Pipeline of next-gen technology Development timelines Budget allocation between R&D and commercialization Intellectual property strategy (patents, trade secrets) Request evidence of technical milestones, not just conceptual roadmaps. c. Competitive Moats Assess whether the company’s innovation is defensible through: Patents Proprietary materials or algorithms Exclusive supply agreements Data advantages High switching costs 6. Team & Operational Execution   a. Founding Team & Technical Expertise Do founders have expertise in energy, engineering, sustainability, hardware, or manufacturing? Have they brought physical technology to market before? b. Organizational Strength Examine structure across engineering, operations, sales, installation, and regulatory functions. Evaluate whether the company has: Solid program/project management Scalable operational processes Strong supply chain and field operations teams c. Execution Metrics Request KPIs such as: Deployment timelines Installation costs Uptime and reliability metrics Warranty claim rates On-time delivery and backlog status Look for signs of operational discipline like documented SOPs and audited processes. 7. Financials & Capital Structure   a. Historical Financials Request: 2–3 years of financial statements Cash flow breakdown (critical for capex-heavy firms) Gross margin trends Equipment and installation cost data Assess whether the company’s growth justifies its burn rate. b. Financial Model & Scenarios Review projections with a focus on: Unit economics under scale Sensitivity to commodity prices Capex requirements for growth Working capital needs (especially for hardware) Installation labor availability Model downside cases: What if incentives drop, cost of materials rises, or deployment slows? c. Cap Table & Funding Requirements Request a detailed cap table including SAFEs, notes, and options. Understand: Existing investor rights Liquidity preferences Future capital needs and dilution risk Dependency on project financing or credit facilities 8. Customer Validation & Market Risk   a. Customer References Speak with customers in pilot or commercial deployments. Ask: Did the technology meet expectations? Was the installation smooth? Did it generate real cost or carbon savings? Would they expand usage? b. Competitive Landscape Map direct and indirect competitors: Incumbents Emerging cleantech startups Cross-category substitutes (e.g., batteries vs. thermal storage) Assess defensibility and switching costs. c. Infrastructure & Channel Risk Evaluate dependencies such as: Utility approval cycles Installation labor availability Supply chain bottlenecks Dependence on one large customer or geographic region 9. ESG, Sustainability & Risk Management   a. Environmental Impact Request lifecycle analyses or carbon footprint data. Verify claims around emissions reduction, recyclability, and energy savings. b. Resilience &

    Read More »

    How to Diligence a Medical Device Startup

    min read How to Diligence a Medical Device Startup How to Diligence a Medical Device Startup A comprehensive investor guide to evaluating clinical value, regulatory risk, and commercialization potential Medical device startups operate within one of the most complex innovation categories, requiring mastery across engineering, clinical medicine, regulation, manufacturing, and reimbursement. For investors, diligence on these companies requires a structured, evidence-based approach that goes far beyond the pitch deck. This guide outlines how to properly diligence a medical device startup, integrating core industry frameworks, regulatory expectations, and the milestone roadmap unique to medtech innovation. Key content to highlight essential metrics, timelines, and development paths. 1. Clinical Problem & Unmet Need Every strong medical device startup begins with a validated, painful clinical problem. The most investable solutions are those that clearly improve outcomes, reduce complications, save clinician time, or reduce healthcare costs. Diligence Questions Is the problem clinically significant and supported by evidence Is the startup solving a proven, unmet need, or is it simply a “nice-to-have”? Does the device fit naturally into a clinician’s workflow? Evidence to Request Peer-reviewed publications Interviews with clinicians (surgeons, nurses, technicians) Hospital pilot interest or letters of support Workflow analysis Clinical validation is not optional; investors should look for early signs that the device will be accepted in practice. 2. Technology, Engineering Maturity & IP Investors must evaluate whether the technology is real, reliable, and defensible. Key Areas to Diligence Prototype functionality (bench testing, usability testing) Software validation (IEC 62304) Human factors engineering (IEC 62366) Reliability and failure mode testing Freedom-to-operate and patent filings Prototypes vs. Clinical Units Prototypes → used for engineering tests and early feedback Clinical unit → the version intended for formal clinical testing Investors should verify that the startup understands and is progressing toward an actual clinical unit, not just a lab prototype. 3. Regulatory Pathway, Risk Class, & Key Metric The regulatory pathway defines cost, timeline, risk, and capital needs. Misjudging it is one of the most common investor mistakes. Your One Key Metric: 510(k) Cycle Time For medical device startups, the key performance metric is not revenue, but rather: Cycle Time Through the 510(k) Application and Approval Process Why? A medical device cannot generate revenue until it receives FDA clearance. The 510(k) process exists to demonstrate that the device is at least as safe and effective as a predicate device already on the market. The typical cycle time ranges from: 50–300 days, depending on device complexity. Investors should ask the startup: What is the standard cycle time for comparable devices? How are you benchmarking against that? What regulatory consultant or QA/RA firm is guiding your path? Understanding this timeline is essential to evaluating execution risk and funding needs. 4. Clinical Evidence, Validation & Trials Investors must examine whether the startup is producing the right evidence at the right time. Core Stages of Clinical Validation Preclinical validation – Initial safety and bench/animal tests First-in-human tests – Early clinical study Clinical validation – Broader human clinical trial data Evidence to Request Cadaver/animal study results Human factors reports Early feasibility human data Biocompatibility and electrical safety testing Strong startups demonstrate a clear, statistically powered plan for pivotal clinical trials, including sites, budget, endpoints, and timeline. 5. Manufacturing, Quality Systems & Supply Chain A medtech startup must eventually scale hardware manufacturing, a central diligence area many investors overlook. Diligence Checklist Design for manufacturability (DFM) Supplier qualification Sterilization pathway and validation Packaging and shelf-life testing ISO 13485-aligned quality management system Without proper QMS and design controls, FDA clearance and manufacturing scale become extremely risky. 6. Reimbursement Strategy & Commercial Model Even with FDA approval, a device can fail commercially without reimbursement. Key Reimbursement Questions Is there an existing CPT, HCPCS, or DRG code? Will a new code be required? What is the economic value to hospitals and providers? Are early health economic studies underway? Strong startups can demonstrate real cost savings or efficiency improvements that justify purchasing. 7. Team, Advisors, & Capital Strategy Execution in medtech requires multidisciplinary excellence. What to Look For Founders with clinical or engineering depth Regulatory and quality expertise Key opinion leaders (KOLs) involved early Experience with device commercialization Capital Planning Medical device development often requires three to five years to reach FDA clearance and initial sales. Investors should verify: Milestone-based fundraising strategy Clear runway aligned to regulatory events. Transparent burn projection 8. The Medical Device Roadmap: A Critical Diligence Tool Medical Device Startup Roadmap Market requirements Product requirements Prototypes Clinical unit Preclinical validation First-in-human test Clinical validation CE Mark (Europe) First European orders 510(k) clearance (US) First US orders Break-even Growth and scale Why this matters for diligence Investors should map the startup’s current stage against this roadmap to evaluate: How far they’ve progressed Whether they are ahead or behind industry norms Whether capital needs align with upcoming milestones What risks remain before revenue is possible This roadmap provides a clear, standardized structure for evaluating readiness and execution risk. Common Red Flags During Diligence No predicate identified for 510(k) No regulatory consultant engaged Confusion between intended use and indications for use Only early prototypes, no pathway to a clinical unit Unrealistic regulatory timelines Limited or no clinical advisor involvement Weak or nonexistent reimbursement plan Underestimation of hospital sales cycles (12–24 months) Diligencing a medical device startup requires a holistic approach that integrates: Clinical need Technology maturity Regulatory strategy 510(k) cycle-time metrics Clinical validation Manufacturing readiness Reimbursement viabilit Team capability Roadmap alignment Capital planning By using these frameworks, especially the medical device roadmap and the 510(k) cycle time regulatory metric, investors can distinguish between a promising concept and a fundable medtech venture capable of achieving clinical and commercial success. Read More from TEN Capital Education here. Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

    Read More »

    How to Diligence a CPG Firm

    7 min read How to Diligence a CPG Firm Diligencing a consumer packaged goods (CPG) business has nuances that set it apart from pure software or marketplace investing. Whether you’re an angel investor, family office, or VC, evaluating a CPG company means diving into supply chain dynamics, product economics, brand strength, and more. Here’s a structured, risk-aware playbook to help you evaluate a CPG firm like a pro. 1. Understand the Business Model & Unit Economics Gross Margins and Cost Structure Ask for a breakdown of the cost of goods sold (COGS): raw materials, packaging, labor, and overhead. Determine how variable costs scale: Does margin improve with volume, or are there fixed costs that drag at low volumes? Verify whether the company’s pricing is sustainable in different sales channels (direct-to-consumer vs. retail). Lifetime Value (LTV) vs. Customer Acquisition Cost (CAC) If the company sells direct to consumers, evaluate repeat purchase behavior: what is the retention rate over 6- and 12-month cohorts? For wholesale distribution, calculate the per-customer margin and reorder frequency. Model LTV in each channel and compare it against CAC across those same channels. Pricing Strategy and Sensitivity How elastic is demand for their products? If costs rise or discounts shrink, how will that impact volume? What is their value narrative — are they competing on premium quality, sustainability, or price? That will shape pricing power. 2. Supply Chain & Manufacturing Risks Sourcing and Raw Materials Who are their suppliers, and how diversified is the supply base? Are there single-source risks? (e.g., only one supplier for a key ingredient.) What is the lead time for critical raw materials, and how volatile are their costs? Manufacturing Capacity & Scalability Where is the product manufactured? In-house, co-packer, or a network of partners? If they use co-packers, do they have contracts in place, and is there slack capacity for scaling? Are there quality control systems? Ask for defect rates, returns, or consumer complaints. Inventory Management What is their inventory turnover? High inventory on hand could indicate demand forecasting risk. How do they manage shelf life, especially for perishable or seasonal products? What’s the working capital tied up in inventory — is it a cash drag? 3. Go-to-Market Strategy Distribution Channels Where do they sell: DTC (direct-to-consumer), brick & mortar retail, grocery chains, or specialty stores? For retail distribution: what’s their push strategy? Do they have favorable slotting terms? What are their trade spend and promotional allowances? For DTC: analyze their customer acquisition channels (paid ads, organic, SEO, email), conversion rates, and cost per acquisition. Brand Strength & Positioning What is the company’s brand story, and how does it resonate with its target customer? Do they have customer testimonials or social proof (e.g., reviews or word of mouth)? How do they differentiate (taste, packaging, sustainability, health angle)? Is this differentiation defensible, or is it easily copied Marketing Efficiency What percentage of revenue is being reinvested into marketing? How efficient are their sales funnels? (e.g., Email open/click rates, ad ROAS, conversion from trial/sample to repeat purchase) Are there community or viral growth vectors (referral programs, user-generated content, influencers) 4. Regulatory and Compliance Considerations Food Safety & Quality Does the CPG company comply with relevant regulatory bodies (FDA in the U.S., local food safety authorities elsewhere) Request documentation such as HACCP plans, food safety audits, or third-party quality certifications (e.g., SQF or BRC). How do they handle product recalls, and what is their track record? Packaging & Labeling Are labels compliant with nutrition, ingredient, and allergen disclosure regulations? Does the firm use any sustainable or recyclable packaging? If yes, how does that impact COGS and supply chain risk? Environmental, Social, Governance (ESG) If ESG is part of their value prop (eco-friendly, local sourcing), verify their claims with evidence, such as supplier audits, lifecycle assessments, carbon impact assessments, etc. Are there sustainability-related liabilities (e.g., packaging waste, carbon offset obligations)? 5. Product & Innovation Evaluation Product-Market Fit Conduct a sensory evaluation: sample the product (if possible) or collect feedback from early customers. Analyze repeat purchase rates, product lifecycle (i.e., are customers buying again, or is it a “try once” product?). How broad is their SKU (stock-keeping unit) mix? Do they plan to expand into new SKUs or adjacent categories? Innovation Pipeline Do they have a roadmap for new flavors, size formats, or product lines? How much of their R&D or product development budget is allocated to innovation vs. core SKUs? Have they tested new products in pilot markets? What were the results? 6. Team & Operational Execution Founders & Leadership What is the founding team’s background? Do they have experience in consumer goods, manufacturing, or retail? Have they scaled a physical product business before, or is this their first CPG venture? Meet the team responsible for operations, supply chain, and quality — are they capable of handling scale? Organizational Structure How is the organization structured across procurement, manufacturing, sales, and marketing? Do they have robust systems for demand forecasting, production planning, and logistics? What is their talent strategy for hiring and retaining people in key roles? Execution Metrics Ask for KPIs such as yield rates, batch failure rates, on-time delivery, inventory shrinkage, and return rates. How quickly have they scaled since launch — both in production volume and sales? What evidence is there of operational discipline (e.g., documented SOPs, contracts with co-packers, audits)? 7. Financial & Capital Structure Historical Financials Request P&L statements, balance sheets, and cash flow for at least the past 2–3 years. Compare their burn rate vs. growth: are they reinvesting heavily, or burning cash without traction? Understand working capital needs: how much cash is tied up in inventory or accounts receivable (especially for retail customers)? Projections & Scenario Modeling Review their financial model: are their assumptions realistic around growth, margins, and cash needs? Run downside and base-case scenarios: what happens if growth slows, COGS rise, or customer acquisition costs increase? How much capital will they need to scale, and what is their runway? Cap Table & Funding History Ask for a full

    Read More »

    How to Diligence a Therapeutic Startup

    7 min reading How to Diligence a Therapeutic Startup “In therapeutic investing, the science must be right, but the strategy must be smarter.” Diligencing a therapeutic startup is unlike any other form of early-stage investing. It requires balancing scientific rigor with business realism. From molecule to market, investors must evaluate not just whether the science works, but also whether the pathway to revenue and, eventually, to exit is both capital-efficient and strategically defensible. In this article, we distill insights from Startup Funding Espresso episodes on diligence, biotech assessment, and founder fit to create a structured playbook for investors, founders, and diligence teams navigating therapeutic innovation. The Purpose of Diligence Therapeutic startups operate at the intersection of science, regulation, and capital markets. The goal of diligence is to validate alignment across three domains: Technical feasibility — Does the underlying science or technology platform hold up under scrutiny? Regulatory viability — Is there a clear pathway through the FDA, EMA, or equivalent agencies? Commercial potential — Is the market large enough, accessible enough, and ready enough to support sustained adoption? The episode “Setting up Due Diligence” underscores that diligence is not a checklist but a risk-reduction process. Each layer, technical, market, financial, and team, reveals not only what’s known but also where uncertainty resides. Key Pillars of Therapeutic Diligence Across episodes like “What Investors Look for in a Biotech Startup”, “Core Skills for Biotech Drug Development”, and “Best Practices for Therapeutic Startup Fundraising,” five diligence pillars consistently emerge: a. Scientific Validity Evaluate the mechanism of action and supporting pre-clinical data. Look for peer-reviewed validation or collaborations with credible institutions. Avoid overreliance on early, non-replicated studies. b. Regulatory Readiness Determine if the company understands its regulatory classification (drug, biologic, device, or combination product). The episode “Key Documents for Your Due Diligence Box” reminds investors to confirm the presence of pre-IND or pre-submission feedback and a mapped timeline to key milestones (IND, Phase I/II/III, etc.). c. Intellectual Property Strong IP defines competitive durability. Diligence teams should verify patent ownership, freedom-to-operate analyses, and upcoming expirations. The episode “Red Flags in Due Diligence” lists weak patent coverage and licensing ambiguity as common deal-killers. d. Market and Reimbursement The episode “How to Diligence the Market” highlights the importance of mapping addressable markets, reimbursement codes, and pricing elasticity early. In therapeutics, the buyer is often not the user; understanding payer dynamics is as critical as clinical efficacy. e. Team and Execution From “How to Diligence the Team” and “How Much Diligence to Run on a Founder,” we learn that successful therapeutic founders combine scientific depth with regulatory and commercial literacy. Look for balanced teams, scientific founders complemented by business operators and regulatory veterans. Evaluating the Science: From Discovery to Translation Scientific diligence is both art and analytics. The episodes “Technical Due Diligence” and “Performing Due Diligence Like a VC” emphasize reviewing: Preclinical data integrity (sample sizes, control design, statistical significance). Translational relevance (animal model to human trial correlation). Scalability of the therapeutic platform (manufacturing, formulation, delivery). Replicability and documentation quality. The diligence process should involve external subject-matter experts who can assess biological plausibility and experimental design. Investors often underestimate how manufacturing complexity and stability testing can become multi-million-dollar bottlenecks post-Series A. Regulatory Diligence: Navigating the FDA Maze Episodes like “Due Diligence: The Thorough Approach” and “Signing NDAs in Due Diligence” note that regulatory diligence is not just about confidentiality; it’s about clarity. Investors should verify: Has the company engaged with the FDA through pre-IND or Q-submission meetings? Does the clinical plan align with regulatory precedent? Are timelines and budgets realistic given the required studies? For devices and diagnostics, the 510(k), De Novo, and PMA pathways drastically change time-to-market and capital requirements. For drugs, investors should validate the clinical endpoints that regulators will recognize and the CMC (Chemistry, Manufacturing & Controls) readiness. Market Validation and Adoption Risk The episodes “How to Perform Marketing Due Diligence” and “The Role of Social Media in Due Diligence” remind us that even brilliant therapies fail if they can’t cross the commercial chasm. Critical diligence questions include: Who pays for this therapy—patients, insurers, or hospitals? What’s the comparative cost versus the current standard of care? How do KOLs (Key Opinion Leaders) view the therapeutic value? Savvy investors go beyond market sizing they look for evidence of early traction, like investigator interest, LOIs from clinics, or grants validating unmet needs. Financial and Risk Diligence In “Financials, Team and Domain Diligence” and “Going Through Due Diligence,” Hall T. Martin highlights the need to align scientific milestones with capital tranches. Key insights include: Link fundraising to de-risking events (e.g., IND submission, Phase I completion). Assess capital efficiency: how much per data point? Model downside scenarios: what happens if the lead candidate fails? Therapeutic startups should demonstrate clear cash-to-value conversion, showing how each dollar accelerates the next stage of validation. Qualitative and Quantitative Diligence From “The Quantitative and Qualitative Side of Due Diligence,” effective investors integrate metrics and intuition. Quantitatively, they evaluate market size, runway, and clinical timelines. Qualitatively, they examine founder motivation, transparency, and resilience. The best diligence blends data with discernment; a founder’s honesty in disclosing failed experiments often signals stronger integrity than perfect slides. Common Red Flags Episodes like “Red Flags in Due Diligence” and “What Isn’t Being Said in Due Diligence” reveal recurring warning signs: Overstated preclinical results or missing negative data. Lack of clarity on IP ownership or licensing. Unrealistic regulatory timelines. Founders are resistant to third-party validation. Weak capitalization structure or unrecorded convertible debt. Any one of these can indicate a lack of maturity in governance or readiness for institutional investment. Building the Due Diligence Box The “Key Documents for Your Due Diligence Box” episode lists must-have files: Executive summary and pitch deck Scientific white papers IP portfolio summary Regulatory correspondence Financial model and cap table Team bios and advisory board profiles For therapeutics, include clinical protocol summaries and manufacturing validation reports. Organizing these early signals professionalism and preparedness. Performing Diligence Like a VC In “Performing Due Diligence Like a VC,” the guidance

    Read More »

    How to Diligence a Marketplace Startup

    10 min read How to Diligence a Marketplace Startup The Hidden Complexity of Marketplace Investing Marketplace startups look deceptively simple—connect buyers and sellers, take a transaction fee, and scale. Yet beneath the surface lies one of the most intricate business models in venture capital. Each marketplace comprises three intertwined systems: supply acquisition, demand generation, and transaction trust. Diligencing such a company requires investors to look beyond vanity metrics and into the structural mechanics that sustain the network. Unlike SaaS or product companies, a marketplace’s moat emerges not from technology alone but from network density, unit economics, and behavioral liquidity. Accurate diligence measures how these forces interact over time—not just whether the platform is growing, but whether it is compounding. 1. Market Definition and Network Dynamics Total Addressable Market (TAM) and Fragmentation Start with clarity on the target market’s size and fragmentation. The best marketplaces often enter highly fragmented, inefficient markets where incumbents lack digital coordination, such as real estate agents, local services, or niche B2B verticals. A large TAM alone isn’t enough; investors should assess whether participants are ready for platformization. Markets with strong offline incumbents or regulatory friction may resist the shift. Ideal markets have: Many small, independent providers have poor discovery tools. High-frequency transactions that encourage repeat use. A clear “pain point” in finding, vetting, or paying counterparties. Two-Sided Liquidity: Solving the Cold Start Problem The cold-start problem — how to attract both sides of the market simultaneously — is the defining risk for early marketplace ventures. During diligence, look for tactical liquidity strategies: Single-vertical focus: Does the company start narrow to seed density before expanding? Demand priming: Are they subsidizing one side (often the supply side) until cross-traffic builds? Community seeding: Is there an existing user base or offline network that can be digitized quickly? Early liquidity in even a small segment signals the flywheel potential that investors prize. 2. Business Model and Unit Economics Revenue Model Fit The most common monetization models include take rates (transaction fees), subscription tiers, and lead-generation fees. Each implies different risk structures. Transaction fees require trust, and an integrated payment is high-value but high-friction. Subscription models indicate recurring revenue but can mask low transaction activity. Lead models work early but limit scalability once competition rises. Investors should ask: Is the monetization aligned with the core user value? A mismatch between value creation and value capture, like charging suppliers before buyers exist, can choke early growth. Economics per Transaction Healthy marketplaces exhibit a positive contribution margin once acquisition costs normalize. During diligence, evaluate: Take rate vs. CAC: Does the average customer transaction justify the acquisition cost? Repeat usage: Is retention improving as users deepen engagement? Cohort profitability: Do earlier cohorts improve over time (a sign of compounding trust)? An investor-grade model includes LTV/CAC ratios above 3x, declining CAC, and evidence that organic or referral traffic is growing faster than paid channels. 3. Supply and Demand Validation Supply-Side Diligence Strong supply is the backbone of marketplace liquidity. Look for evidence of supply stickiness: Contracts, integrations, or switching costs that prevent churn. Platform tools that embed suppliers’ inventory management, CRM, and analytics. Precise segmentation of high-value vs. low-value suppliers. Investors should scrutinize how supply quality is maintained at scale. The best marketplaces curate, not just aggregate through reputation systems, ratings, or algorithmic filtering. Demand-Side Diligence Demand validation is equally critical. Look for signals of habitual usage: Percentage of users completing transactions vs. browsing. Repeat rate within 30–90 days. Conversion from search to transaction. If acquisition is primarily through paid channels, ask whether organic channels (SEO, referrals, word of mouth) are growing. A healthy marketplace eventually “earns” its traffic through brand trust and liquidity, not just ad spend. 4. Trust, Safety, and Transaction Infrastructure Trust is the invisible currency of marketplaces. Investors often underestimate the importance of dispute resolution, escrow systems, and user verification. Diligence questions to ask: How does the platform mitigate fraud or low-quality interactions? Is there buyer and seller verification? How quickly are disputes resolved? What share of GMV occurs on-platform versus off-platform? A marketplace with a strong safety reputation accelerates network effects. Each satisfied user adds both volume and confidence to future participants. 5. Technology, Data, and Defensibility Technology as an Enabler, Not the Moat While marketplaces are technology-enabled, their defensibility lies more in data loops than in code. Assess: Proprietary matching algorithms or dynamic pricing systems. Unique datasets built from repeated transactions. Predictive analytics is improving the balance between supply and demand. Technology amplifies the moat once scale is achieved, but rarely substitutes for it. Diligence should confirm that technology shortens the distance between intent and transaction. Network Effects and Switching Costs Ask: Do more users make the platform better for all participants? Are switching costs increasing (data lock-in, reputation scores, embedded tools)? Is there evidence of local network effects, city-by-city or niche-by-niche density? True network effects are measurable: declining CAC, improving retention, and rising transaction frequency as density grows. 6. Regulatory and Operational Risks Marketplaces often enter semi-regulated sectors (transportation, healthcare, finance). Investigate compliance exposure early: Licensing or labor classification risks (e.g., gig economy). Data privacy or payment compliance (PCI, GDPR). Local versus national jurisdiction variance. Operational diligence should review internal controls—how the company handles disputes, refunds, and payment reconciliation. Hidden liabilities here can erode margins later. 7. Team, Culture, and Execution Capability In marketplaces, execution discipline matters as much as vision. Founders must balance product growth with operational rigor. Red flags include: Overemphasis on growth without tracking unit economics. Weak analytical culture or reliance on anecdotal success stories. Lack of expertise in supply-chain or logistics for physical marketplaces. Green flags include: Founders who deeply understand both sides of the market. Clear frameworks for scaling liquidity (e.g., city rollout models). Experienced data and operations leadership. Diligence should include references and operator interviews with those who have scaled networks before, as they are rare and invaluable. 8. Investor Fit and Exit Pathways Investors must map the marketplace’s growth to their own fund model. Marketplaces can deliver large exits but often require long gestation periods before compounding effects take hold. Key investor diligence checkpoints: Time to liquidity: Are transaction volumes doubling

    Read More »

    How to Diligence a Deeptech Startup

    5 min read How to Diligence a Deeptech Startup Deeptech investing sits at the frontier of science and innovation where research, engineering, and commercialization intersect. Unlike pure software startups, deeptech ventures build defensible advantages through hard science: novel materials, AI hardware, quantum systems, robotics, medtech, or energy storage breakthroughs. These opportunities are exciting but also carry unique risks. Traditional venture diligence frameworks often fall short when technology readiness, regulatory hurdles, and manufacturing scalability dominate the risk stack. This article distills key lessons from Startup Funding Espresso episodes on diligence, technology risk, and commercialization. The goal: to help investors and founders apply a structured, evidence-based approach to evaluating deeptech startups. Why Deeptech Diligence Is Different Every deeptech company compresses three risk domains—science, engineering, and market adoption into a single domain. The challenge is not just whether the technology works, but whether it can be built repeatedly, validated independently, and sold at scale. Traditional diligence focuses on traction and market fit; deeptech diligence begins earlier, with proof-of-concept data, IP defensibility, and regulatory feasibility. Investors must verify not only what exists today but also how quickly risk can be reduced per dollar invested. Key mindset shifts include: From forecasting revenue to mapping technology readiness. From tracking KPIs to testing falsifiable hypotheses. From scaling growth to scaling evidence. 1. Technology and IP — The Foundation of Value The first diligence lens is technical validation. Investors must separate scientific promise from engineering reality. Ask: What has been independently demonstrated, and what remains unproven? Use a Technology Readiness Level (TRL) framework to map progress: TRL 3–5: Lab validation and prototype proof-of-concepts. TRL 6–7: Pilot or limited field trials with defined performance metrics. TRL 8–9: Qualified production systems ready for deployment. Request replicable data, third-party lab results, prototype test reports, and failure analyses. Look for structured experimentation and defined “next proof milestones.” Equally critical is IP defensibility. Strong patent portfolios are not measured by quantity but by claim strength, enforceability, and market coverage. Review patent claims with a freedom-to-operate (FTO) analysis and assess continuation plans. Green flags: independent validation, multiple claims granted, clear continuation strategy.Red flags: single provisional filings, overlapping prior art, or reliance on unprotected trade secrets. 2. Regulatory and Standards Pathway Many deeptech sectors—especially medtech, energy, and advanced materials face heavy regulatory oversight. Evaluate: Applicable standards and certifications (FDA, CE, UL, ISO, ITAR, etc.). Defined testing phases, costs, and lead times. How compliance and certification are budgeted within the funding round. A credible startup presents stage-gated plans, design verification, safety testing, and third-party audits with clear contingency budgets. Failing to anticipate certification hurdles can derail commercialization even when performance is strong. 3. Manufacturing and Supply Chain Deeptech ventures live or die by manufacturing scalability. A prototype in a lab is far from a product on a production line. Focus diligence on: Design for Manufacturability: Has the team engineered around tolerances, yield loss, and cost variability? Supplier validation: Are key materials single-sourced or dual-qualified? Cost curves: Does the company model BOM reduction as a function of volume? Unit economics should improve with scale—not degrade under real-world conditions. Review supplier references, pilot production data, and yield reports, along with contingency plans for critical components. 4. Market Validation and Go-to-Market Strategy Deeptech adoption is slower and more conservative. Market traction is measured by pilots, paid proofs of concept (POCs), and letters of intent (LOIs), not user downloads. Ask: Who are the anchor customers? Are there signed pilots with success metrics? Do successful pilots convert to purchase orders or rollout commitments? Look for evidence of market pull rather than push. Strong startups identify a beachhead market, a narrow, high-value initial use case to expand from once technical and regulatory risks are reduced. 5. Business Model and Unit Economics Deeptech success depends on translating innovation into a sustainable business. Assess: Pricing logic: value-based or cost-plus. Service model: warranty, maintenance, support obligations. Margin progression: gross margin by production lot and expected BOM reductions. Validate a clear path to profitability once production stabilizes. Many deeptech companies underestimate hidden costs tooling, certification renewals, and warranty exposure. Confirm how gross margins evolve with scale and how service costs are managed. 6. Team and Execution Capability Winning deeptech teams blend: Scientific depth (core technology and IP creation). Engineering discipline (system integration, QA, and reliability). Commercial skill (enterprise sales and regulatory navigation). Assess whether the team balances technical and operational expertise, or knows when to bring in external expertise. Signs of execution maturity: Detailed experiment and pilot schedules. Hiring plans tied to risk milestones. Advisors or board members with relevant domain expertise. The best teams demonstrate self-awareness and a plan to close capability gaps as they grow. 7. Financial and Capital Planning In deeptech, capital efficiency equals risk reduction per dollar spent. Each round should connect the capital directly to the risk milestones: Proof of principle → validated prototype. Prototype → regulatory clearance or pilot. Pilot → scaled production or recurring revenue. Ensure the round fully funds the next de-risking event. Partial funding during critical phases, such as certification, can dramatically increase failure risk. Common Red Flags Reliance on anecdotal or non-replicable data. Undefined or unrealistic regulatory timelines. Missing supplier validation for long-lead components. Pilots without success criteria or written commitments. IP limited to provisional filings without FTO analysis. When several appear together, they signal structural risks, not minor gaps. Clear Green Flags Independent third-party validation of test data. Detailed regulatory roadmap with time and budget estimates. Qualified manufacturing partners and early yield data. Paid pilot contracts with expansion pathways. Documented BOM and cost-reduction roadmap. These signals indicate a company transitioning from research to execution, where investors can confidently participate in scaling innovation. Read More from TEN Capital Education here.

    Read More »

    Site Map

    Scroll to Top